Johns Hopkins offers a wide array of specialists from surgery, interventional radiology, radiation oncology and oncology all dedicated to treating liver cancer. In addition to standard approaches to liver cancer, Johns Hopkins also offers clinical trails.

Below is a list of the clinical trails currently open or soon to open at Johns Hopkins.

  1. J0516: Treatment of Patients with Hepatocellular Carcinoma using Drug-Eluting Bead Embolization. This study uses drug-eluting beads in chemoembolization of liver cancer.
    Primary Investigator: Dr. J. Geschwind.
  2. Upcoming: TACE/Avastin administered in interventional radiology. This adds a VEGF inhibitor to standard TACE treatment or liver cancer.
    Primary Investigator: Dr. J. Geschwind.
  3. Upcoming: Phase II trial of erlotinib (Tarceva) and bevacizumab (Avastin) for patients with advanced HCC. Novel combination of targeted therapies in liver cancer.
    Primary Investigator: Dr. Manuel Hidalgo